Clinuvel Pharmaceuticals Limited (CLVLF)
USD 7.45
(2.05%)
USD 7.45
(2.05%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -182.98 Million AUD | -17.44% |
| 2023 | -155.81 Million AUD | -29.57% |
| 2022 | -120.25 Million AUD | -47.75% |
| 2021 | -81.38 Million AUD | -24.39% |
| 2020 | -65.42 Million AUD | -21.53% |
| 2019 | -53.83 Million AUD | -48.73% |
| 2018 | -36.19 Million AUD | -52.4% |
| 2017 | -23.75 Million AUD | -71.56% |
| 2016 | -13.84 Million AUD | -30.95% |
| 2015 | -10.57 Million AUD | 27.71% |
| 2014 | -14.62 Million AUD | -16.36% |
| 2013 | -12.56 Million AUD | 1.18% |
| 2012 | -12.71 Million AUD | -4.44% |
| 2011 | -12.17 Million AUD | 37.27% |
| 2010 | -19.41 Million AUD | 10.57% |
| 2009 | -21.71 Million AUD | 15.69% |
| 2008 | -25.75 Million AUD | 23.9% |
| 2007 | -33.84 Million AUD | -293.24% |
| 2006 | -8.6 Million AUD | -80.69% |
| 2005 | -4.76 Million AUD | 13.1% |
| 2004 | -5.48 Million AUD | -109.83% |
| 2003 | -2.61 Million AUD | 40.83% |
| 2002 | -4.41 Million AUD | 36.77% |
| 2001 | -6.98 Million AUD | 11.94% |
| 2000 | -7.92 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -38.1 Million AUD | 75.55% |
| 2024 Q2 | -37.74 Million AUD | 0.93% |
| 2024 Q4 | -182.98 Million AUD | 0.0% |
| 2024 FY | -182.98 Million AUD | -17.44% |
| 2023 Q2 | -139.56 Million AUD | 0.23% |
| 2023 Q3 | -156.11 Million AUD | -11.86% |
| 2023 Q1 | -139.89 Million AUD | -16.33% |
| 2023 Q4 | -155.81 Million AUD | 0.19% |
| 2023 FY | -155.81 Million AUD | -29.57% |
| 2022 Q2 | -97.82 Million AUD | 0.27% |
| 2022 Q4 | -120.25 Million AUD | 0.26% |
| 2022 Q1 | -98.08 Million AUD | -20.52% |
| 2022 Q3 | -120.56 Million AUD | -23.25% |
| 2022 FY | -120.25 Million AUD | -47.75% |
| 2021 FY | -81.38 Million AUD | -24.39% |
| 2021 Q4 | -81.38 Million AUD | 0.32% |
| 2021 Q1 | -71.78 Million AUD | -9.71% |
| 2021 Q3 | -81.64 Million AUD | -14.12% |
| 2021 Q2 | -71.54 Million AUD | 0.33% |
| 2020 Q3 | -65.63 Million AUD | -14.91% |
| 2020 Q2 | -57.12 Million AUD | 0.43% |
| 2020 FY | -65.42 Million AUD | -21.53% |
| 2020 Q1 | -57.36 Million AUD | -6.56% |
| 2020 Q4 | -65.42 Million AUD | 0.32% |
| 2019 Q4 | -53.83 Million AUD | 0.48% |
| 2019 Q1 | -42.82 Million AUD | -18.31% |
| 2019 Q2 | -42.82 Million AUD | 0.0% |
| 2019 Q3 | -54.09 Million AUD | -26.32% |
| 2019 FY | -53.83 Million AUD | -48.73% |
| 2018 Q3 | -36.19 Million AUD | -29.56% |
| 2018 Q4 | -36.19 Million AUD | 0.0% |
| 2018 Q1 | -27.93 Million AUD | -17.63% |
| 2018 FY | -36.19 Million AUD | -52.4% |
| 2018 Q2 | -27.93 Million AUD | 0.0% |
| 2017 Q4 | -23.75 Million AUD | 0.0% |
| 2017 FY | -23.75 Million AUD | -71.56% |
| 2017 Q3 | -23.75 Million AUD | -21.49% |
| 2017 Q2 | -19.55 Million AUD | 0.0% |
| 2017 Q1 | -19.55 Million AUD | -41.21% |
| 2016 FY | -13.84 Million AUD | -30.95% |
| 2016 Q4 | -13.84 Million AUD | 0.0% |
| 2016 Q3 | -13.84 Million AUD | -84.63% |
| 2016 Q2 | -7.49 Million AUD | 0.0% |
| 2016 Q1 | -7.49 Million AUD | 29.07% |
| 2015 Q2 | -11.97 Million AUD | 0.0% |
| 2015 FY | -10.57 Million AUD | 27.71% |
| 2015 Q1 | -11.97 Million AUD | 18.09% |
| 2015 Q4 | -10.57 Million AUD | 0.0% |
| 2015 Q3 | -10.57 Million AUD | 11.75% |
| 2014 FY | -14.62 Million AUD | -16.36% |
| 2014 Q2 | -9.74 Million AUD | 0.0% |
| 2014 Q1 | -9.74 Million AUD | 22.45% |
| 2014 Q3 | -14.62 Million AUD | -50.05% |
| 2014 Q4 | -14.62 Million AUD | 0.0% |
| 2013 Q4 | -12.56 Million AUD | 0.0% |
| 2013 Q3 | -12.56 Million AUD | 0.0% |
| 2013 FY | -12.56 Million AUD | 1.18% |
| 2012 Q4 | -12.71 Million AUD | 0.0% |
| 2012 FY | -12.71 Million AUD | -4.44% |
| 2011 Q4 | -12.17 Million AUD | 0.0% |
| 2011 FY | -12.17 Million AUD | 37.27% |
| 2010 FY | -19.41 Million AUD | 10.57% |
| 2010 Q4 | -19.41 Million AUD | 0.0% |
| 2009 Q4 | -21.71 Million AUD | 0.0% |
| 2009 FY | -21.71 Million AUD | 15.69% |
| 2008 FY | -25.75 Million AUD | 23.9% |
| 2008 Q4 | -25.75 Million AUD | 0.0% |
| 2007 Q4 | -33.84 Million AUD | 0.0% |
| 2007 FY | -33.84 Million AUD | -293.24% |
| 2006 FY | -8.6 Million AUD | -80.69% |
| 2006 Q4 | -8.6 Million AUD | 0.0% |
| 2005 Q4 | -4.76 Million AUD | 0.0% |
| 2005 FY | -4.76 Million AUD | 13.1% |
| 2004 FY | -5.48 Million AUD | -109.83% |
| 2004 Q4 | -5.48 Million AUD | 0.0% |
| 2003 Q4 | -2.61 Million AUD | 0.0% |
| 2003 FY | -2.61 Million AUD | 40.83% |
| 2002 Q4 | -4.41 Million AUD | 0.0% |
| 2002 FY | -4.41 Million AUD | 36.77% |
| 2001 FY | -6.98 Million AUD | 11.94% |
| 2000 FY | -7.92 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 20.27 Million USD | 1002.489% |
| Skye Bioscience, Inc. | -5.72 Million USD | -3098.326% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -2802.498% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -73206.901% |
| Qrons Inc. | 351.42 Thousand USD | 52170.184% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 4191.866% |
| CSL Limited | 10.52 Billion USD | 101.738% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 527.614% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 3339.672% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 28909.539% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 521.303% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -896551.74% |
| Rebus Holdings, Inc. | 305 Thousand USD | 60096.291% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -13968502.061% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 29502.197% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 921168.541% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 1260.875% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 4543.604% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 45636.678% |
| SQZ Biotechnologies Company | -36.23 Million USD | -404.964% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 8261.002% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 19835.92% |
| Mesoblast Limited | 55.85 Million USD | 427.595% |
| Marizyme, Inc. | 18.56 Million USD | 1085.451% |
| Genus plc | 190.6 Million USD | 196.007% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 8284.367% |
| Pharming Group N.V. | 109.8 Million USD | 266.65% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 21371.793% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 15174.594% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 27010.101% |
| ContraFect Corporation | -6.02 Million USD | -2936.653% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 136010.611% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 15937.294% |
| IMV Inc. | 7.67 Million USD | 2485.61% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 3425.921% |
| MultiCell Technologies, Inc. | 90.04 USD | 203230538.694% |
| ONE Bio Corp. | 9.04 Million USD | 2124.203% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -24831.086% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 1513.477% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 13476.65% |
| Q BioMed Inc. | 4.06 Million USD | 4607.102% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 698.903% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 18258.756% |
| Biomind Labs Inc. | 711.4 Thousand USD | 25822.262% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 402.232% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 9252.217% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 1528.863% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 50971.17% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 130989.45% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 8410.185% |
| GB Sciences, Inc. | 1.74 Million USD | 10572.558% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -99465.09% |
| HST Global, Inc. | 96.79 Thousand USD | 189151.571% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 88835.985% |
| Halberd Corporation | 144.72 Thousand USD | 126542.387% |
| Enzolytics Inc. | 981.65 Thousand USD | 18740.816% |
| Agentix Corp. | 37.63 Thousand USD | 486371.125% |
| Resverlogix Corp. | 6.45 Million USD | 2936.594% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -27086.403% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 90.981% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -289.238% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 2687.886% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 6855.803% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -1970.028% |
| AVAX Technologies, Inc. | -5.9 Million USD | -2999.818% |
| Zenith Capital Corp. | 10.06 Thousand USD | 1818350.07% |
| Genscript Biotech Corporation | -1.06 Billion USD | 82.759% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 91397.142% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 7769.157% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 111333.238% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -998855.601% |
| Kadimastem Ltd | -253.1 Thousand USD | -72198.396% |
| Helix BioMedix, Inc. | -2.57 Million USD | -7020.094% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 91024.248% |
| LadRx Corporation | -2.03 Million USD | -8885.587% |
| Cell Source, Inc. | 9.23 Million USD | 2082.119% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 28909.539% |
| NovAccess Global Inc. | 2.17 Million USD | 8499.891% |
| Affymax, Inc. | -5.59 Million USD | -3169.407% |
| Itoco Inc. | 228.3 Thousand USD | 80250.977% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 134661.389% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 3791.521% |
| Mobile Lads Corp. | 484.23 Thousand USD | 37889.466% |
| CytoDyn Inc. | 20.26 Million USD | 1003.113% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -28282540.958% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -1974241.543% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 2474.625% |
| SYBLEU INC | 473.71 Thousand USD | 38728.516% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 4205.627% |
| International Stem Cell Corporation | 2.59 Million USD | 7165.2% |
| Bioxytran, Inc. | 1.89 Million USD | 9736.492% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 293290.02% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 8490.512% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 5428.733% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 2239.468% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 23784.575% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -14539.095% |
| Neutra Corp. | 52.18 Thousand USD | 350740.364% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -7251.896% |
| PureTech Health plc | -167.19 Million USD | -9.445% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -74617.317% |
| IXICO plc | -4.44 Million USD | -4017.113% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 1484.285% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 433.61% |
| CSL Limited | 10.52 Billion USD | 101.738% |
| Cellectis S.A. | -43.81 Million USD | -317.602% |